| ziltivekimab (COR-001) / Novo Nordisk |
2020-004853-59: ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation ZEUS- klinikinis tyrimas kuriuo stebima kaip veikia Ziltevikimabas lyginant su placebo žmonėms su terosklerozinė širdies ir kraujagyslių liga, lėtinė inkstų liga bei sisteminiu uždegimu |
|
|
| Ongoing | 3 | 6200 | Europe, RoW | Ziltivekimab B 15 mg/mL DV3430-C1, [.], Solution for injection | Novo Nordisk A/S, NOVO NORDISK. S.P.A., Novo Nordisk A/S | Atherosclerotic cardiovascular diseaseChronic kidney disease Systemic inflammation aterosklerozinė širdies ir kraujagyslių liga,lėtinė inkstų liga sisteminis uždegimas, Cardiovascular diseaseChronic kidney diseaseInflammation aterosklerozinė širdies ir kraujagyslių liga,lėtinė inkstų liga sisteminis uždegimas, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 3 | 40 | NA | Ziltivekimab, no other intervention name, Placebo | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Atherosclerosis, Inflammation | 03/25 | 04/25 | | |
ATHENA, NCT06200207: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation |
|
|
| Recruiting | 3 | 680 | Europe, Canada, US, RoW | Ziltivekimab, Placebo | Novo Nordisk A/S | Heart Failure, Systemic Inflammation | 10/26 | 01/27 | | |
ZEUS, NCT05021835 / 2020-004853-59: - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation |
|
|
| Recruiting | 3 | 6200 | Europe, Canada, Japan, US, RoW | Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C) | Novo Nordisk A/S, Novo Nordisk A/S | Cardiovascular Risk, Chronic Kidney Disease, Inflammation | 09/25 | 01/26 | | |
ARTEMIS, NCT06118281: - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, Japan, US, RoW | Ziltivekimab, Placebo | Novo Nordisk A/S, Duke Clinical Research Institute | Cardiovascular Risk, Acute Myocardial Infarction (AMI) | 09/26 | 09/26 | | |
HERMES, NCT05636176: A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation |
|
|
| Recruiting | 3 | 5600 | Europe, Canada, Japan, US, RoW | Ziltivekimab, Placebo | Novo Nordisk A/S | Heart Failure | 07/27 | 07/27 | | |
2022-004078-53: Impact of inflammation lowering on plaques and systemic inflammation Impact van ontsteking verlaging op plaques en systemische ontsteking |
|
|
| Ongoing | 2 | 40 | Europe | Ziltivekimab, NA, Solution for injection | Academic Medical Center (AMC), department of Internal Medicine, Academic Medical Center (AMC), department of Internal Medicine | - Plaque characteristics- Systemic inflammation - Plaque karakteristieken- Systemische inflammatie, - Plaque features- Inflammation - Aderverkalking kenmerken- Ontsteking, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT05379829: A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation |
|
|
| Active, not recruiting | 1 | 24 | RoW | Ziltivekimab, Placebo | Novo Nordisk A/S | Chronic Kidney Disease and Systemic Inflammation | 05/24 | 05/24 | | |
NCT05721989: A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab |
|
|
| Completed | 1 | 267 | Europe | Ziltivekimab B, Ziltivekimab D, Ziltivekimab C | Novo Nordisk A/S | Healthy Participants | 01/24 | 01/24 | | |
